Evidence-based Approaches to Diagnose, Treat, and Manage Patients With Retinal Diseases

2.25 CME
135 MINS
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Evidence-based Approaches to Diagnose, Treat, and Manage Patients With Retinal Diseases


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education

Support Statement

This activity is supported by independent medical education grants from Alcon Vision, LLC; Genentech, a member of the Roche Group; and Regeneron Pharmaceuticals, Inc.

Activity Description

The COVID-19 pandemic has created many challenges for the continued education and training of ophthalmology and retinal physicians. However, medical and surgical algorithms for the management of patients with retinal diseases have continued to evolve and current management protocols further refined. To address some of these ongoing challenges, this activity will provide evidence-based approaches to diagnose, treat, and manage these patients. An expert panel of retina specialists will address conventional and new diagnostic modalities for early diagnosis and monitoring of retinal diseases, and assess evidence-based protocols and best practices for the medical and surgical management of retinal diseases.

Target Audience

The intended audience for this activity is retina specialists, ophthalmologists, and other health care professionals involved in the management of patients with retinal disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Summarize the degenerative and inflammatory processes associated with the pathophysiology of retinal vascular disorders to better understand potentially beneficial treatments.
  • Describe conventional and new diagnostic modalities that can improve the early detection of retinal diseases.
  • Examine advances in imaging that can improve diagnosis, treatment, and monitoring of retinal disorders.
  • Assess evidence-based medicine and best practices for the medical management of retinal diseases.
  • Analyze the results of key clinical trials relating to the treatment of retinal vascular disorders to assist in clinical decision-making.
  • Assess new evidence regarding the use of multimodal therapeutic regimens in the treatment of retinal vascular disorders.
  • Evaluate the evidence and best practices relating to the surgical management of retinal disorders.

Activity Chair

Rishi P. Singh, MD
Staff Physician
Center for Ophthalmic Bioinformatics
Cole Eye Institute
Cleveland Clinic Foundation
Professor of Ophthalmology
Lerner College of Medicine
Case Western Reserve University
Cleveland, OH


Jorge A. Fortun, MD
Associate Professor of Ophthalmology
Bascom Palmer Eye Institute
Miami, FL

Andrew A. Moshfeghi, MD, MBA
Associate Professor of Clinical Ophthalmology
Medical Director of the USC Roski Eye Institute
Director of Clinical Trials
Director of the Retina Fellowship Program
Keck Medicine of USC
Los Angeles, CA

Prithvi Mruthyunjaya, MD, MHS
Associate Professor of Ophthalmology and Radiation Oncology
Director, Ocular Oncology Service
Director, Vitreoretinal Surgery Fellowship
Byers Eye Institute at Stanford University
Palo Alto, CA

Planning Committee

Sunil K. Srivastava, MD
Staff Physician
Cole Eye Institute
Cleveland Clinic
Cleveland, OH


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.

Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn credits equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, November 17, 2021, to November 16, 2022.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of 6 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.  

Activity Chair, Planning Committee, and Faculty report the following relationship(s)

Jorge A. Fortun, MD
Consulting Fee: Alcon, Alimera, Allergan, Novartis, Zeiss
Contracted Research: Genentech, Novartis

Andrew A. Moshfeghi, MD, MBA
Consulting Fee: Allergan, Genentech/Roche, Novartis, Ocular Therapeutix, Placid0, Pr3vent, Regeneron
Contracted Research: Genentech/Roche, Novartis, Regeneron
Ownership Interest: Ocular Therapeutix, OptiStent, Placid0, Pr3vent

Prithvi Mruthyunjaya, MD, MHS
Consulting Fee: Alcon, Aura Biosciences, Castle Biosciences

Rishi P. Singh, MD
Consulting Fee: Alcon, Apellis, Genentech, Gyroscope, Novartis, Regeneron, Zeiss
Contracted Research: Aerie, Apellis, Graybug Vision

Sunil K. Srivastava, MD
Consulting Fee: Adverum, Bausch + Lomb, jCyte, Novartis, Regeneron, Zeiss
Contracted Research: EyePoint, Gilead, Regeneron, Santen

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicoCME.com